14:17 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and mouse studies suggest PROK2 could help treat PD. In a rat dopaminergic neural cell line pretreated with the neurotoxicant 1-methyl-4-phenylpyridinium (MPP) to induce PD-like pathology, PROK2 decreased caspase-3...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Prokineticin 2 (PROK2; Bv8); prokineticin receptor 2 (PROKR2; PKR2) Rat studies suggest inhibiting PROK2 signaling could help treat stroke. In...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Prokinectin 2 (PROK2; Bv8); G-CSF (CSF3) Mouse studies suggest that inhibiting G-CSF or Bv8 could help treat cancer. In mice with metastatic breast tumors,...
07:00 , Sep 3, 2009 |  BC Innovations  |  Targets & Mechanisms

Bv8: main pain player

While Roche 's Genentech Inc. unit has been busy unraveling the role of Bv8 in tumor angiogenesis, 1-3 a team of Italian researchers has shown that the target also plays an essential role in inflammatory...
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Prokineticin 2 (PROK2; Bv8); prokineticin receptor 1 (PROKR1; PKR1); PROKR2 (PKR2) Studies in rodents suggest that inhibiting PROK2, PKR1 or PKR2 could treat inflammatory...
07:00 , May 11, 2009 |  BioCentury  |  Strategy

Latent Value Finds a Home

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc....
07:00 , Apr 9, 2009 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Granulocyte macrophage colony-stimulating factor (CSF2; GM-CSF); VEGF; prokineticin 2 (PROK2; Bv8) Studies in mice suggest that targeting GM-CSF or...
07:00 , Sep 1, 2008 |  BC Week In Review  |  Clinical News

Semafore preclinical data

In renal and prostate cancer cell lines, and in human brain endothelial cells, SF1126 inhibited the ability of vascular endothelial growth factor (VEGF) and Prokineticin 2 ( PROK2 , Bv8 ) to activate protein kinase...
08:00 , Mar 6, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Prokineticin 2 (PROK2; Bv8) A study in mice suggests that antagonizing Bv8 could be useful for treating early-stage cancers. In...
08:00 , Feb 7, 2008 |  BC Innovations  |  Targets & Mechanisms

Unraveling Bv8

Researchers at Genentech Inc. have added three big pieces to the puzzle of how prokineticin 2 ( PROK2 ; Bv8 ), a cytokine secreted by myeloid cells in the bone marrow, regulates tumor-related angiogenesis. The...